372例患者新型抗肿瘤药物使用合理性分析  

Application Rationality of Novel Antitumor Drugs in 372 Patients

作　　者：施嫣嫣[1] 黄玉宇 SHI Yanyan;HUANG Yuyu(Dept.of Pharmacy,Suzhou Traditional Chinese Medicine Hospital Affiliated to Nanjing University of Chinese Medicine,Jiangsu Suzhou 215009,China)

机构地区：[1]南京中医药大学附属苏州市中医医院药学部,江苏苏州215009

出　　处：《中国医院用药评价与分析》2025年第2期220-222,226,共4页Evaluation and Analysis of Drug-use in Hospitals of China

基　　金：国家中医药管理局“十二五”重点专科培育项目(No.苏中医政〔2012〕13号)。

摘　　要：目的:探讨该院新型抗肿瘤药物临床应用合理性。方法:采用回顾性调查分析方法,通过医院信息系统(HIS)汇总2022年1月1日至2024年1月1日该院使用新型抗肿瘤药物患者的用药信息,评价用药合理性,分析用药特征。结果:共纳入372例患者,使用新型抗肿瘤药物共1473例次,其中192例次存在不合理,不合理率为13.03%。主要表现为未完善基因检测(75例次,占5.09%)、无循证医学证据超适应证使用新型抗肿瘤药物(34例次,占2.31%)、用法与用量不适宜(45例次,占3.05%)及联合用药不适宜(38例次,占2.58%)。结论:该院新型抗肿瘤药物的临床应用存在部分不合理,医院应建全规章制度、定期组织专项培训,临床医师应规范处方行为,药师应加强处方审核干预等,提高新型抗肿瘤药物的临床应用合理性。OBJECTIVE:To probe into the rationality of clinical application of novel antitumor drugs in the hospital.METHODS:Retrospective investigation and analysis were conducted to summarize the drug application characteristics of patients with novel antitumor drugs in the hospital from Jan.1st,2022 to Jan.1st,2024 through hospital information system(HIS)system,the rationality and drug application characteristics were evaluated and analyzed.RESULTS:A total of 372 patients were enrolled,and 1473 cases of novel antitumor drugs were used,among which 192 cases were irrational,and the irrational rate was 13.03%.The main manifestations were incomplete gene detection(75 cases,5.09%),application of novel antitumor drugs without evidence-based medical evidence(34 cases,2.31%),inappropriate usage and dosage(45 cases,3.05%)and improper drug combination(38 cases,2.58%).CONCLUSIONS:The clinical application of novel antitumor drugs in the hospital is partly irrational.The hospital should establish regulations and regularly organize special training for clinicians to standardize the prescription behavior and for pharmacists to strengthen the prescription review and intervention,so as to improve the rational application of novel antitumor drugs in clinical practice.

关 键 词：新型抗肿瘤药物 用药合理性 基因检测 超适应证 

分 类 号：R979.1[医药卫生—药品] R969.3[医药卫生—药学]